Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00571649 · ClinicalTrials.gov registry record · Phase 3
Venous Thromboembolic Event (VTE) Prophylaxis in Medically Ill Patients
A Phase 3 study, sponsored by Bayer.
- Completed
- Registry status
- Phase 3
- Development phase
- 8,101
- Enrollment target
NCT00571649: Completed Phase 3 study, sponsored by Bayer.
NCT00571649 is a Phase 3 study that has completed, run by Bayer. The registered enrollment target is 8,101 participants, above the 771-participant average among 15,282 other Phase 3 trials with a reported enrollment target (951% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00571649, a Phase 3 study, has completed, sponsored by Bayer.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 8,101 participants
- Enrollment target
Study Summary
This study will evaluate if extended therapy with oral rivaroxaban can prevent blood clots in the leg and lung that can occur with patients hospitalized for acute medical illness, and compare these results with those of the standard enoxaparin dose and duration regimen. The safety of rivaroxaban will also be studied.
Primary Outcome
A composite endpoint of: asymptomatic proximal DVT in lower extremity detected by mandatory bilateral lower extremity venous ultrasonography; symptomatic DVT in lower extremity, proximal or distal; symptomatic, non-fatal PE; and VTE-related death.
Interventions
- DRUG Enoxaparin
- DRUG Rivaroxaban (Xarelto, BAY59-7939)
- DRUG Rivaroxaban placebo
- DRUG Enoxaparin placebo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8,101 participants |
| Start Date | 2007-12 |
| Est. Completion | 2010-11 |
| Phase | Phase 3 |
What the finished NCT00571649 record still lists
NCT00571649 is an interventional study that assigns participants to a tested intervention. Its 8,101 participants enrollment target places it among the larger protocols in the corpus, above the 771-participant average among 15,282 other Phase 3 trials with a reported enrollment target (951% higher).
The record links to 0 conditions, and to 4 interventions - of which Enoxaparin is the first listed.
NCT00571649 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00571649 about?
NCT00571649 is a clinical study titled "Venous Thromboembolic Event (VTE) Prophylaxis in Medically Ill Patients". This study will evaluate if extended therapy with oral rivaroxaban can prevent blood clots in the leg and lung that can occur with patients hospitalized for acute medical illness, and compare these results with those of the standard enoxaparin dose and duration regimen. The safety of rivaroxaban wil...
What is the current status of trial NCT00571649?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 8,101 participants. The study started on 2007-12. Estimated completion is 2010-11.
What interventions are being tested in trial NCT00571649?
The interventions under investigation include: Enoxaparin (DRUG), Rivaroxaban (Xarelto, BAY59-7939) (DRUG), Rivaroxaban placebo (DRUG), Enoxaparin placebo (DRUG).
Who is sponsoring clinical trial NCT00571649?
This trial is sponsored by Bayer, which has 591 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00571649's enrollment target sits among peer trials
8,101 32nd of 2000 higher than 1,969 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06184945 · 8,100 participants · NA
Behavioral Economic & Staffing Strategies in the ICU
- NCT05593484 · 8,060 participants · NA
School Screening and Telemedicine Specialty Referral to Address Childhood Hearing Loss in Rural Alaska
- NCT06435806 · 8,200 participants · NA
Medical Illustration Design Characteristic Evaluation
- NCT00539162 · 8,000 participants · NA
Use of the CA 125 Algorithm for the Early Detection of Ovarian Cancer in Low Risk Women
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia